Erasca, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
Erasca, Inc. (ERAS) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $14.98 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2024-11-12
- 2024-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $14.98M.
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $22.28M.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $9.96M.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $19.75M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2024-09-30 | $14.98M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $22.28M 10-Q · filed 2024-08-12 |
| 2023-09-30 | $9.96M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $19.75M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $29.48M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $44.05M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |